ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

CD8+ T Cells Differentiate into a CD43-expressing Effector Population After Transplantation

G. Cohen, M. A. Kallarakal, S. M. Krummey

Department of Pathology, Johns Hopkins University, Baltimore, MD

Meeting: 2022 American Transplant Congress

Abstract number: 622

Keywords: Co-stimulation, T cell activation, T cells

Topic: Basic Science » Basic Science » 02 - Acute Rejection

Session Information

Session Name: Acute Rejection

Session Type: Poster Abstract

Date: Saturday, June 4, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 5:30pm-7:00pm

Location: Hynes Halls C & D

*Purpose: Despite a significantly reduced toxicity profile and improved long-term graft function versus calcineurin inhibitors, widespread adaptation of belatacept (CTLA-4 Ig) has been limited due to acute rejection. Deeper understanding of relevant effector T cell populations that mediate acute rejection will lead to more targeted strategies to prevent it. Following priming, expression of numerous surface receptors has been used to describe effector CD8+ T cell populations in different models. However, the phenotype of CD8+ T cell effectors after transplantation is not well understood. We sought to characterize the phenotype of effector CD8+ T cells that are elicited following grafting in order to identify directed therapeutic approaches to inhibit them.

*Methods: We used a fully allogeneic Balb/c H-2(d) into C57BL/6 H-2(b) mice skin graft model. We utilized an MHC Class I tetramer, H-2L(d)/QL9 peptide, in order to identify antigen-specific CD8+ T cells in the spleen and draining lymph nodes following transplantation. CD8+ T cells were assessed using multiparameter flow cytometry with both FlowSOM clustering and conventional gating.

*Results: Skin grafting resulted in the expansion of CD44+ L(d)/QL9-specific CD8+ T cells, with a peak in absolute number and Ki67+ at day 10 post-graft. FlowSOM identified a cluster of CD8+ effector T cells expressing activated CD43 receptor (clone 1B11) that was elevated at day 10 and decreased at memory timepoints (Day 0 vs Day 10 p=0.0020). CD43+ CD8+ T cells expressed high levels of Ki67 and Granzyme B relative to CD43– CD8+ T cells (Ki67 p<0.0001, Granzyme B p=0.0035). When stimulated with H-2(d) antigen, the CD43+ CD8+ T cells population expressed a higher frequency of IFN-gamma (CD43– 22.82 ± 9.61% vs CD43+ 73.82 ± 9.99%, p=0.0480). CD43+ CD8+ T cells were also formed following CTLA-4 Ig treatment, indicating resistance to CD28 blockade. On day 10, CD43+ CD8+ T cells expressed high levels of ICOS in the presence of CTLA-4 Ig, suggesting that ICOS is a potential therapeutic target. Treatment with both CTLA4-Ig and ICOS antibody resulted in prolonged Balb/c skin graft survival versus CTLA-4 Ig alone (p=0.0094).

*Conclusions: Using MHC Class I tetramers, we identified a population of CD43+ CD8+ T cells which are potent effectors. This CD43+ population also expresses high levels of ICOS, even in the presence of CTLA-4 Ig. Future experiments will seek to understand the dynamics of CD43+ effector function in vivo and identify strategies to inhibit their function.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Cohen G, Kallarakal MA, Krummey SM. CD8+ T Cells Differentiate into a CD43-expressing Effector Population After Transplantation [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/cd8-t-cells-differentiate-into-a-cd43-expressing-effector-population-after-transplantation/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences